Multicenter evaluation of crystal violet decolorization assay (CVDA) for rapid detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis
| Autor: | Mustafa Ozyurt, Meltem Uzun, Nuran Delialioğlu, Ismail Ceyhan, Ali Korhan Sig, Nilay Ucarman, Can Biçmen, Suheyla Surucuoglu, Ahmet Yilmaz Coban, Nurhan Albayrak, Aydan Özkütük, Bayhan Bektöre, Nuran Esen, Ahmet Ugur Akbal, Ali Albay, Gönül Aslan, Deniz Sertel Selale, Nuri Özkütük, Alpaslan Alp |
|---|---|
| Přispěvatelé: | OMÜ |
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Tuberculosis Time Factors 030106 microbiology Drug resistance Microbial Sensitivity Tests Calorimetry Rapid detection Sensitivity and Specificity Article Microbiology Mycobacterium tuberculosis 03 medical and health sciences chemistry.chemical_compound Tuberculosis Multidrug-Resistant medicine Isoniazid Humans Crystal violet Multidisciplinary biology business.industry Developed Countries medicine.disease biology.organism_classification Multiple drug resistance chemistry Gentian Violet Rifampin business Rifampicin medicine.drug |
| Zdroj: | Scientific Reports |
| ISSN: | 2045-2322 |
| Popis: | Sig, Ali Korhan/0000-0003-2907-257X; Akbal, Ahmet Ugur/0000-0002-0627-5326 WOS: 000389886500001 PubMed: 27982061 The aim of this multicenter study was to evaluate the performance of the crystal violet decolorization assay (CVDA) for detection of multidrug resistant tuberculosis (MDR-TB). This study was performed in 11 centers in two phases. A total of 156 isolates were tested for INH and RIF resistance. In the phase I, 106 clinical isolates were tested in the Center 1-7. In the phase 2, 156 clinical isolates were tested in the center 1-6, center 8-11. Eighty six of 156 tested isolates were the same in phase I. Agreements were 96.2-96.8% for INH and 98.1-98.7% for RIF in the phase I-II, respectively. Mean time to obtain the results in the phase I was 14.3 +/- 5.4 days. In the phase II, mean time to obtain the results was 11.6 +/- 3.5 days. Test results were obtained within 14days for 62.3% (66/106) of isolates in the phase I and 81.4% (127/156) of isolates in the phase II. In conclusion, CVDA is rapid, reliable, inexpensive, and easy to perform for rapid detection of MDR-TB isolates. In addition, it could be adapted for drug susceptibility testing with all drugs both in developed and developing countries. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|